Detection of Atrial Fibrillation After Cardiac Surgery (SEARCH-AF)

• ClinicalTrials.gov Identifier: NCT02793895
• Recruitment Status: Recruiting
• First Posted: June 8, 2016
• Last Update Posted: July 15, 2020
• Sponsor: Unity Health Toronto
• Information provided by (Responsible Party): Unity Health Toronto

Study Description

Brief Summary:

The aim of the SEARCH-AF trial is to evaluate a novel diagnostic tool for detecting post-operative atrial fibrillation or flutter (POAF/AFL) in cardiac surgical subjects during the early, sub-acute post-operative period. The population includes cardiac surgical subjects who have either developed or are at risk for developing new onset POAF/AFL and who are at risk for stroke, as determined by their CHA2DS2-VASC (congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, previous stroke/transient ischemic attack (TIA) (2 points), vascular disease, age 65-74 years, sex class (female)) score. These subjects must not have had a history of AF/AFL before cardiac surgery.

The intervention group will undergo up to 30 days of continuous cardiac rhythm monitoring with an adhesive, patch-based monitor (Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device). The control group will receive usual care, which does not involve planned cardiac rhythm testing within the first 30 days after study randomization. The primary outcome is documentation of sustained atrial fibrillation or flutter within the first 30 days after randomization. In addition, subjects in both groups will undergo 14 days of continuous cardiac rhythm monitoring with the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device at 6±1 months after their index cardiac surgery.

Condition or disease	Intervention/treatment	Phase
Atrial Fibrillation; Atrial Flutter; C.Surgical Procedure; Cardiac; Arrhythmias, Cardiac	Device: Medtronic SEEQ™ mobile cardiac telemetry system; Other: Usual Care; Device: CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device	Not Applicable

Detailed Description:

The aim of the SEARCH-AF trial is to evaluate a novel diagnostic tool for detecting post-operative atrial fibrillation or flutter (POAF/AFL) in cardiac surgical subjects during the early, sub-acute post-operative period. Its primary objective is to test whether enhanced cardiac rhythm monitoring with an adhesive, continuous monitor results in higher rates of atrial fibrillation or flutter (AF/AFL) detection at 30 days after randomization for post-cardiac surgical subjects who are at risk for developing post-operative atrial arrhythmias, when compared to usual care.

The study design is an open-label, two-arm randomized controlled trial (RCT) comparing a strategy of enhanced cardiac rhythm monitoring vs. usual care in 396 post-cardiac surgical subjects who are at risk for developing POAF/AFL.

The primary endpoint is the proportion of subjects with a cumulative AF/AFL burden of ≥6 minutes or documentation of AF/AFL by a 12-lead ECG within 30 days after randomization. Clinical endpoints will be adjudicated by an independent committee of physicians.

The study population involves post-cardiac surgical subjects at high risk of stroke, defined as having a CHA2DS2-VASC score of ≥4 or CHA2DS2-VASC of ≥2 with additional risk factors for developing POAF/AFL. These subjects must not have a history of AF/AFL pre-operatively.

Subjects who meet inclusion criteria will be randomized in a 1:1 ratio to one of the following 2 arms: (i) Enhanced cardiac rhythm monitoring (intervention group) or (ii) Usual care (control group). Subjects in the intervention group will receive up to 30 days of continuous cardiac rhythm monitoring with the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. Monitoring will begin on the day of randomization. Subjects in the usual care group will not undergo protocol-mandated cardiac rhythm monitoring during the first 30 days after randomization.

All subjects will have a follow-up visit at 31-90 days after hospital discharge and at 6±1 months after surgery. At 6±1 months, all subjects will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. A telephone follow-up will be performed for all subjects at 9±1 months after surgery.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 396 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Post-Surgical Enhanced Monitoring for Cardiac Arrhythmias and Atrial Fibrillation (SEARCH-AF): A Randomized Controlled Trial
• Actual Study Start Date: February 24, 2017
• Estimated Primary Completion Date: December 2020
• Estimated Study Completion Date: December 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Enhanced cardiac rhythm monitoring; Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.	Device: Medtronic SEEQ™ mobile cardiac telemetry system; The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.; Device: CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device; The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
Active Comparator: Usual care; Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.	Other: Usual Care; For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.

Outcome Measures

Primary Outcome Measures :

1. Number of participants with a cumulative atrial fibrillation/flutter (AF/AFL) duration of ≥6 minutes or documentation of AF/AFL by a 12-lead electrocardiogram [ Time Frame: Within 30 days of randomization. ]
   The primary endpoint of this trial is documentation of sustained AF/AFL, defined as a cumulative AF/AFL duration of ≥6 minutes or documentation of AF/AFL by a 12-lead ECG within 30 days after randomization. Clinical endpoints will be adjudicated by an independent clinical events committee.

Secondary Outcome Measures :

1. Number of participants with atrial fibrillation or flutter lasting for ≥24 hours. [ Time Frame: (i) Within 30 days of randomization and (ii) Between day 31 and the last follow-up date. ]
   This outcome will be measured by a continuous cardiac modality (e.g. Holter, Event monitor, SEEQ™ mobile cardiac telemetry system, CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device).
2. Duration of cumulative atrial fibrillation or flutter burden amongst participants. [ Time Frame: Between day 31 of randomization and the last follow-up date. ]
   This outcome will be measured by a continuous cardiac modality (e.g. Holter, Event monitor, SEEQ™ mobile cardiac telemetry system, CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device).
3. Number of participants who are prescribed with oral anticoagulation for atrial fibrillation or flutter-related stroke prevention. [ Time Frame: (i) Within the first 45 days after discharge from cardiac surgery; (ii) Between day 46 and the last follow-up date. ]
   This outcome will be collected during study follow-up visits.
4. Number of days during which the adhesive Medtronic SEEQ™ or CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device was worn by participants. [ Time Frame: (i) Within 30 days after randomization (intervention group only); (ii) Between day 31 and the last follow-up date (all subjects). ]
   This outcome will be collected during study follow-up visits.
5. Number of participants who prematurely remove the adhesive Medtronic SEEQ™ or CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. [ Time Frame: (i) Within 30 days after randomization (intervention group only); (ii) Between day 31 and the last follow-up date (all subjects). ]
   This outcome will be collected during study follow-up visits.
6. Number of participants with adverse events related to the use of the Medtronic SEEQ™ or CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. [ Time Frame: (i) Within 30 days after randomization (intervention group only); (ii) Between day 31 and the last follow-up date (all subjects). ]
   This outcome will be collected during study follow-up visits.
7. Number of participants who undergo non-protocol mandated Holter monitoring and/or event recorders. [ Time Frame: (i) Within 30 days after randomization; (ii) Between day 31 and the last follow-up date. ]
   This outcome will be collected during study follow-up visits.
8. Hospitalization or emergency room visits. [ Time Frame: Within the first 45 days after hospital discharge from index cardiac surgery. ]
   This outcome will be collected during study follow-up visits.
9. Major adverse cardiac outcomes. [ Time Frame: (i) Within the first 45 days after hospital discharge from index cardiac surgery; (ii) Between day 46 and the last follow-up date. ]
   All-cause death, myocardial infarction, ischemic stroke, non-CNS systemic embolism.
10. Number of participants with bleeding events. [ Time Frame: (i) Within the first 45 days after hospital discharge from index cardiac surgery; (ii) Between day 46 and the last follow-up date. ]
    Major bleeding.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female age ≥18 years.
2. Isolated CABG or valve replacement/repair +/- CABG performed at the index surgical procedure.

3. At elevated risk of stroke and for having POAF/AFL, defined as having a CHA2DS2-VASC (congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, previous stroke/transient ischemic attack (TIA) (2 points), vascular disease, age 65-74 years, sex class (female)) score of ≥4 or ≥2 with at least 1 of the following risk factors for developing POAF/AFL:

   (i) Chronic obstructive pulmonary disease; (ii) Sleep apnea; (iii) Impaired renal function (defined as creatinine clearance <60 ml/min/1.73m2 or <60 ml/min); (iv) Echocardiographic evidence of at least mild left atrial enlargement (defined as ≥41 mm on M-mode, ≥59 ml or ≥29 mL/m2 on biplane volume assessment from an echocardiogram performed within 12 months of study enrollment); (v) Elevated body mass index (defined as BMI ≥30); (vi) Combined surgery (CABG + valve repair/replacement).

4. Able to provide written informed consent.

Exclusion Criteria:

1. Atrial fibrillation or flutter at the time of randomization.
2. Known previous history of AF/AFL, diagnosed pre-operatively (note: documentation of a history of AF/AFL without accompanying rhythm proof will suffice).
3. Documentation of continuous AF/AFL for ≥24 hours during the in-hospital stay for the index cardiac surgery.
4. Subjects who, at the discretion of the treating cardiac surgery team, would be treated and discharged with oral anticoagulation due to POAF/AFL.
5. Mechanical valve replacement.
6. Current or anticipated treatment with oral anticoagulation for indications other than AF/AFL.
7. Hospitalization for ≥10 days (for the index cardiac surgery, with day #0 being the day of surgery).
8. Planned discharge from hospital with a type IC or III anti-arrhythmic drug.
9. Having received >5 grams of IV and/or oral amiodarone during hospitalization for the index cardiac surgical procedure.
10. Women of childbearing potential (WOCBP).
11. History of percutaneous or surgical left atrial ablation for AF.
12. Presence of a cardiac implantable electronic device with a functioning atrial lead (pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization device).
13. Presence of an implantable loop recorder.
14. History of left atrial appendage ligation, removal, or occlusion.
15. Subjects with known allergies or hypersensitivities to adhesives or hydrogel.
16. Inability to provide written informed consent.
17. Current or anticipated participation in another randomized controlled trial in which the interventional drug or device is known to affect the incidence of the primary or secondary outcomes of this study.

Contacts and Locations

Contacts

Contact: Andrew CT Ha, MD; 416-340-5206; andrew.ha@uhn.ca

Contact: Samantha Saes; 416-864-6060 ext 77048; Samantha.Saes@unityhealth.to

Locations

Canada, Manitoba

St. Boniface General Hospital; Recruiting

Winnipeg, Manitoba, Canada, R2H 2A6

Contact: Wendy Janz wjanz@hsc.mb.ca

Principal Investigator: Michael Yamashita, MD

Canada, New Brunswick

Saint John Regional Hospital; Recruiting

Saint John, New Brunswick, Canada, E2L 4L2

Contact: Carole Dube CSResearch@HorizonNB.ca

Principal Investigator: Craig Brown, MD

Canada, Ontario

Kingston General Hospital; Recruiting

Kingston, Ontario, Canada, K7L 2V7

Contact: Deborah Dumerton Shore Deborah.DuMertonShore@kingstonhsc.ca

Principal Investigator: Tarit Saha, MD

Southlake Regional Health Centre; Recruiting

Newmarket, Ontario, Canada, L3Y 3S9

Contact: Christi Darby christi.darby.raconsulting@gmail.com

Principal Investigator: Kevin Teoh, MD

University of Ottawa Heart Institute; Active, not recruiting

Ottawa, Ontario, Canada, K1Y 4E9

St. Michael's Hospital; Recruiting

Toronto, Ontario, Canada, M5B1W8

Contact: Shira Brodutch shira.brodutch@unityhealth.to

Principal Investigator: Subodh Verma, MD

Principal Investigator: Bobby Yanagawa, MD

University Health Network; Recruiting

Toronto, Ontario, Canada, M5G 2C4

Contact: Ann Hill ann.hill@uhn.ca

Principal Investigator: Andrew Ha, MD

Principal Investigator: Terry Yau, MD

Canada, Quebec

Université Laval; Recruiting

Quebec City, Quebec, Canada, G1V 4G2

Contact: Hugo Tremblay hugo.tremblay@criucpq.ulaval.ca

Principal Investigator: Frederic Jacques, MD

Canada

Foothills Medical Centre; Recruiting

Calgary, Canada, T2N 4N1

Contact: Darlene Ramadan ramadan@ucalgary.ca

Principal Investigator: Alexander Gregory, MD

Mazankowski Alberta Heart Institute; Recruiting

Edmonton, Canada, T6G 2B7

Contact: Jeffrey Cheng Jeffrey.Cheng@albertahealthservices.ca

Principal Investigator: Jeevan Nagendran, MD, PhD

Sponsors and Collaborators

Unity Health Toronto

Investigators

• Principal Investigator: Andrew CT Ha, MD; University Health Network, Toronto
• Principal Investigator: Atul Verma, MD; St. Michael's Hospital and Southlake Regional Health Centre
• Principal Investigator: Subodh Verma, MD, PhD; Unity Health Toronto

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yanagawa B, Ad N, Gaudino MF. Commentary: Postoperative atrial fibrillation can last years? Oh snap! J Thorac Cardiovasc Surg. 2020 Apr;159(4):1417-1418. doi: 10.1016/j.jtcvs.2019.04.028. Epub 2019 Apr 24.

• Responsible Party: Unity Health Toronto
• ClinicalTrials.gov Identifier: NCT02793895
• Obsolete Identifiers: NCT04145648
• Other Study ID Numbers: SEARCH-AF-001
• First Posted: June 8, 2016
• Last Update Posted: July 15, 2020
• Last Verified: July 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Unity Health Toronto:

Atrial fibrillation/flutter; Postoperative atrial arrhythmia; Cardiac surgery; Stroke prevention; Oral anticoagulation; Cardiac rhythm monitoring

Additional relevant MeSH terms:

Atrial Fibrillation; Arrhythmias, Cardiac; Atrial Flutter; Heart Diseases; Cardiovascular Diseases; Pathologic Processes